BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tß4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. No effects related to muscle function or fibrosis and no adverse reactions were observed in the mice. Mdx mice are used as models for Duchenne muscular dystrophy to evaluate potential therapeutic compounds. According to the research team, “In exercised dystrophin deficient mice, chronic administration of Tß4 increased the number of regenerating fibers in skeletal muscle and could have a potential role in the treatment of skeletal muscle disease in Duchenne muscular dystrophy.” Because Tß4 stimulates cell migration and anti-apoptosis pathways in skeletal muscle cultures, these data further suggest a role for Tß4 in muscle degenerative diseases and injury.
